STAAR Surgical Company (NASDAQ:STAA) Stock Has Consensus Price Target of $29.00

Shares of STAAR Surgical Company (NASDAQ:STAA – Get Free Report) have earned a consensus rating of “Hold” from the thirteen brokerages that are covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $29.00.

A number of research firms have recently commented on STAA. Zacks Research raised STAAR Surgical from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 19th. Weiss Ratings reissued a “sell (d+)” rating on shares of STAAR Surgical in a research note on Wednesday, November 11th. Stifel Nicolaus raised STAAR Surgical from a “hold” rating to a “buy” rating and increased their target price for the stock from $28.00 to $31.00 in a research note on Tuesday, September 29th. Wall Street Zen upgraded shares of STAAR Surgical from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Finally, Veritas Investment Research set a $31.00 price target on shares of STAAR Surgical in a research note on Tuesday, September 29th.

Get Our Latest Report on STAA

Institutional Investors Weigh In On STAAR Surgical

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Two Seas Capital LP lifted its holdings in shares of STAAR Surgical by 22.6% in the third quarter. Two Seas Capital LP now owns 1,304,957 shares of the medical instruments supplier’s stock valued at $29,505,000 after purchasing an additional 240,568 shares in the last quarter. Quantinno Capital Management LP acquired a new position in shares of STAAR Surgical during the first quarter worth about $1,109,000. B. Riley Wealth Advisors Inc. bought a new position in shares of STAAR Surgical during the third quarter worth about $546,000. Renaissance Technologies LLC grew its holdings in shares of STAAR Surgical by 257.7% during the first quarter. Renaissance Technologies LLC now owns 135,200 shares of the medical instruments supplier’s stock worth $2,528,000 after buying an additional 97,400 shares in the last quarter. Finally, American Capital Management Inc. raised its position in STAAR Surgical by 18.7% in the 1st quarter. American Capital Management Inc. now owns 878,035 shares of the medical instruments supplier’s stock valued at $16,419,000 after buying an additional 138,499 shares during the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

STAAR Surgical Stock Down 1.4%

Shares of STAA stock opened at $26.01 on Thursday. STAAR Surgical has a 12-month low of $15.59 and a 12-month high of $35.87. The firm has a fifty day moving average of $23.02 and a 200-day moving average of $23.85. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -2,601,000.00 and a beta of 1.22.

STAAR Surgical (NASDAQ:STAA – Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.06. STAAR Surgical had a return on equity of 8.43% and a net margin of 0.16%. The firm had revenue of $83.41 million for the quarter, compared to analyst estimates of $78.73 million. During the same period in the previous year, the company posted $0.08 earnings per share. The company’s revenue for the quarter was down 11.9% on a year-over-year basis. Research analysts expect that STAAR Surgical will post 0.43 earnings per share for the current year.

STAAR Surgical announced that its Board of Directors has initiated a stock buyback program on Thursday, September 24th that authorizes the company to repurchase $50 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 5.2% of its shares through open market purchases. Share buyback programs are typically a sign that the company’s leadership believes its stock is undervalued.

STAAR Surgical Company Profile

(Get Free Report)

STAAR Surgical is a medical device company focused on ophthalmic surgery and vision correction. The company develops, manufactures and markets implantable lenses and related products designed to reduce or eliminate dependence on glasses or contact lenses. Its principal product line is the EVO Visian Implantable Collamer Lens (ICL), a lens implanted inside the eye to correct myopia, with or without astigmatism. Unlike procedures that remove corneal tissue, ICL surgery preserves the eye’s natural lens and is designed to be removable.

Featured Stories

Analyst Recommendations for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.